ADVANZ PHARMA Corp. Acquires International Rights to Two Medicines

Press Releases —

ADVANZ PHARMA Acquires Global Rights to Rare Disease Specialty Brand Zavesca®

Learn more

Press Releases —

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Learn more

Press Releases —

Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe

Learn more

Press Releases —

ADVANZ PHARMA and PHARMATHEN Expand Strategic Partnership with Exclusive License and Supply Agreement

Learn more